☰

InSphero

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of InSphero's published strategy and is not endorsed by, or produced in cooperation with, InSphero. Company website

Strategic priorities

InSphero operates across 4 stated priorities, with the most concrete near-term plan anchored on industrialization of new approach methodologies (nams).

Moving beyond academic microfluidic prototypes to deliver "assay-ready" and "automation-friendly" 3D cell culture systems meeting rigorous pharmaceutical R&D reproducibility standards through ANSI/SLAS-compatible Akura™ plate technology.

Expanding from single-tissue models to interconnected "Body-on-a-Chip" systems replicating physiological interactions between organ types through Akura™ Flow and Akura™ Immune Flow platforms with gravity-driven perfusion.

use the DOPPL SA acquisition to capture patient-specific variations through expanded biobanking and organoid assay development, creating 3D tumor spheroids mimicking in vivo conditions for personalized drug discovery.

Challenges we see

  • Manufacturing Labor

    Bioproduction Orchestration and Kinetic Alignment

    Transition from simple spheroid cultures to sophisticated multi-organ systems requires synchronized production of disparate biological assets with significantly different maturation times and media requirements.

    If one organ model fails QC or maturation kinetics are misaligned, the entire multi-tissue assembly is compromised, with 57% of laboratory personnel lacking specialized knowledge for complex digital and biological orchestration tasks.

  • R&D Digital

    Microfluidic Reliability and Mechanical Friction Points

    Traditional microfluidic systems suffer from "Type A" design flaws including cumbersome tubing, connection ports prone to leakage, and non-specific binding of hydrophobic compounds to PDMS materials.

    A single air bubble in the microchannel system can block flow, alter pressure responses, and exert adverse shear stress on cell cultures, leading to total experimental failure and acting as a barrier to "Plug & Play" adoption.

  • Digital Transformation Labor

    Digital Hesitancy and Cultural Adoption Gap

    Despite advanced automation and 3D modeling tools availability, highly skilled scientists exhibit "Black Box Anxiety" and "Digital Hesitancy," preferring manual Excel islands, paper notebooks, and physical USB drives for data transfer.

    This cultural lag prevents realization of "Lights Out" operation model; operators who distrust automated algorithms frequently revert to manual modes, undermining digital platform ROI and increasing GxP violation risks.

  • IT Infrastructure Digital

    Legacy IT/OT Spaghetti and Data Interoperability

    InSphero's operational landscape and that of global pharmaceutical partners is characterized by heterogeneous equipment fleets including legacy PLCs, GC-MS instruments, and bioreactors from multiple vendors operating in isolation.

    Data islands prevent unified "Source-to-Scientist" data work, necessitating manual transcription violating ALCOA+ principles, slowing regulatory submissions and increasing operational overhead.

  • Operations Manufacturing

    Scaling Patient-Derived Model Production

    The DOPPL SA acquisition and expanded organoid capabilities require scaling patient-derived model production while maintaining tumor morphology and stromal integrity in vitrified models.

    Inconsistent biobanking protocols and complex patient-specific tissue processing can cause batch variability, compromising the reproducibility required for pharmaceutical validation studies.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. High-Stakes Bioproduction Orchestration

    Manual coordination of maturation times for multiple organ models in multi-tissue experiments is a high-risk process where a single failure in one component ruins the entire 32-condition chip assembly.

    Implementation of an "Adaptive Biotech Asset" lifecycle management framework using Industry 5.0 modular units and automated validation to ensure 100% success in complex organ network assembly.

  2. Paper-Based Compliance Risk

    Laboratory data is frequently locked in physical logbooks or local instrument memory, making real-time oversight and trend analysis impossible while increasing manual transcription error risk.

    Deployment of an integrated Laboratory Execution System (LES) acting as a "Single Source of Truth" to eliminate 100% of paper records and provide a secure, immutable electronic audit trail compliant with 21 CFR Part 11.

  3. Disconnected Data Ecosystems

    Equipment from different manufacturers operates in isolation, requiring technicians to use "Excel islands" and USB sticks for data transfer, delaying time-to-insight for researchers.

    Implementing OPC UA and MTP standards as a secure communication backbone to bridge the gap between lab-floor instruments (OT) and corporate analytics (IT), enabling a smooth "Source-to-Scientist" data work.

  4. Technician Skill Gaps and Onboarding Latency

    57% of laboratory staff lack specialized technical knowledge required for sophisticated digital tools, leading to long onboarding times and frequent manual workarounds.

    Utilizing AR/VR-based "Digital Onboarding" modules and assisted reality glasses to facilitate safe, immersive training on complex 3D modeling equipment and remote troubleshooting.

  5. Microfluidic System Reliability

    Complex "initial bubble-free liquid filling" requirements and mechanical sensitivity of microfluidic systems act as barriers to industrial adoption of organ-on-chip technology in high-volume settings.

    Deploying closed-loop process control with computer vision monitoring to detect and mitigate flow anomalies in real-time, enabling autonomous operation of gravity-driven perfusion systems.

What we'd propose

  • Digital Lab

    Managed Support & Lifecycle Management

    Shifting from transactional project models to a continuous partnership service ensuring stability and validation of advanced biotech assets in live production environments.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Digital Lab - Laboratory Execution System (LES)

    A comprehensive digitization service replacing paper-based legacy workflows with an integrated platform for automated data capture and real-time GxP compliance.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Industrial Data Platform (OPC UA & MTP)

    Engineering a secure, vendor-agnostic middleware layer to unify disparate lab and manufacturing equipment into a standardized digital ecosystem.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Digital Advisory & User Experience Design

    Bridging the gap between scientific expertise and digital algorithms through human-centric interface design and structured onboarding programs.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Process Intelligence & Closed-Loop Control

    Implementing real-time bioprocess monitoring with computer vision and AI-driven control algorithms for autonomous operation of microfluidic systems.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what InSphero's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Interoperability 35 → 95
Current state relies on legacy PLCs and disconnected lab instruments; target requires unified OPC UA/MTP backbone for "Plug & Produce" flexibility.
Workforce Digital Readiness 43 → 90
57% documented skill gap in handling sophisticated software; target requires "Digital Native" mindset through immersive training and structured UX onboarding.
Compliance & GxP Automation 40 → 100
Operations involve manual transcription and paper logbooks; target requires 100% automated data capture and real-time GxP validation via integrated LES.
Process Intelligence 28 → 85
Analysis is largely retrospective and fragmented across "Excel islands"; target requires real-time bioprocess Digital Twins and AI-ready ontology-based data platforms.
Asset Lifecycle Management 30 → 95
Current release cycles and validation are often transactional and reactive; target requires proactive "Managed Support" loop with 100% baseline FAT success.
Sustainability Transparency 50 → 90
While InSphero has voluntarily adopted CS3D, current value chain tracking is nascent; target requires automated sustainability passports and audit trails.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with InSphero, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].